Navigation Links
A consistent decline in heart attack rates following the implementation of smoking bans

Strongly enforced legislation to restrict smoking produces rapid and substantial reductions in community rates of heart attack, according to a meta-analysis published today in Circulation, the journal of the American Heart Association.(1) The analysis pooled 13 studies from regions in North America, Italy, Scotland and Ireland and, despite their geographical range, found a consistent reduced risk of hospitalisation for heart attack (acute myocardial infarction, AMI) of 17% (ie, a relative risk for AMI of 0.83) at 12 months following implementation of the law. The investigators added that this benefit "grows with time", reaching a gain of "about 36%" in three years.

The study was designed to determine the "consistent" effect of smoking bans on AMI rates in communities, and was therefore concerned with both the direct and second-hand effects of smoking. Several studies have shown that the effects of second-hand smoke on many biological mediators associated with AMI risk occur rapidly and are nearly as large as those from direct smoking. For example, a study reported last year showed that passive exposure to second-hand smoke in as short a time as 24 hours led to "sustained vascular injury" characterised by reduced endothelial function and activity of endothelial progenitor cells.(2) According to the American Heart Association's Heart Disease and Stroke Statistics 2009 Update, non-smokers exposed to second-hand smoke at home or at work have a 25-30% increased risk of developing heart disease.

Since the first smoking bans were introduced (the first in Europe was in 2004 in Ireland) there have been many reports showing a decline in hospital admissions for AMI following implementation. Indeed, such laws are the best current examples of a clear association between prevention policies and cardiovascular disease. In Europe reduced AMI rates following smoking bans have been reported from France (15% decrease), Italy (11.2%), and Ireland (11%). There have been several studies from Scotland, where smoking has been prohibited by law in all enclosed public places since March 2006. A prospective study of all patients admitted to nine Scottish hospitals with acute coronary syndromes (ACS) found that the number of ACS admissions decreased from 3235 to 2684 following the smoking ban - a 17% reduction.(3) This figure (the same as that now found in the present meta-analysis) compared with a 4% reduction seen in England over the same study period (where no such legislation was in place at the time), and a mean annual decrease of 3% in Scotland during the decade preceding the study.

More recently, results from two other studies have been made public:

  • Research commissioned by the UK's Department of Health found a sharp reduction in the number of hospital admissions for AMI in England in the year following introduction of the public smoking ban in July 2007. The research was reported as "incomplete", with no precise figures given.
  • Research from Iceland presented at the ESC Congress 2009 showed that a nationwide smoking ban in public places resulted in a 21% reduction in ACS admissions among non-smoking men in the five months after the ban was introduced in June 2007. (No such effect was seen in women.) The study population comprised 378 patients (281 men, 97 women) who underwent coronary angiography for ACS during the five months immediately before or after the ban was enacted.(4)

Commenting on the Circulation meta-analysis for the European Society of Cardiology, Professor Joep Perk from Oskarshamn District Hospital in Sweden said: "This is an exciting and important study, with implications for both basic scientists and for politicians."

"First, what the analysis shows is that the harmful effect of second-hand smoke is much greater than we first imagined. It also shows that the benefits derived from the anti-smoking legislation continue over time in a linear direction. The findings, however - although impressive - still pose a challenge to our basic scientists to explain the biology of such benefits and the mechanisms which lie behind them.

"At the public health level the results strengthen the case for anti-smoking legislation in all jurisdictions. There are still many countries in Europe without nationwide legislation, and this study should now provide the tool for wider implementation and the encouragement for braver political decisions. There seems no reason why the EU should not now advocate strong legislation in all member states. Studies like these strengthen the case for preventive cardiology."

Professor Perk noted that all 13 studies contributing to the meta-analysis were observational in methodology; implementation of any new anti-smoking legislation, he proposed, would also provide the framework for a large-scale prospective study to unequivocally confirm the observational findings.


Contact: ESC Press Office
European Society of Cardiology

Related medicine news :

1. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
2. Public Health and Need for Consistent Standards Preclude Exception for Breastfeeding Mother in National Medical Licensing Test
3. Spate of Staph Infections Highlight the Need for Thorough, Consistent Cleaning Regimen at Home, at School and at Work
4. New Report Finds 16 Percent of All Children in Florida Dont Have Consistent Access to Meals
5. New Report Finds 16 Percent of All Children in Nebraska Dont Have Consistent Access to Meals
6. Consistent, Managed Treatment Works Best for Children With AD/HD
7. Key Risk Factors for Suicide Consistent Across Globe
8. Integrium Introduces Its Integrium Clinical Excellence (ICE) Methodology to Assure Consistent Delivery of Sponsor Clinical Trials
9. MD On-Line Achieves CAQH CORE(TM) Certification for Consistent Healthcare Administrative Data Exchange
10. USAs largest ever prostate cancer screening program shows high compliance and consistent results
11. Delusions associated with consistent pattern of brain injury
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of ... 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session on ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the ... LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making the ... a version of Asterisk that will receive not only security fixes, but feature ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology: